Welcome to our dedicated page for Humana news (Ticker: HUM), a resource for investors and traders seeking the latest updates and insights on Humana stock.
Humana Inc. (NYSE: HUM) is a U.S. healthcare company in the direct health and medical insurance carriers industry, with operations spanning insurance services and CenterWell health care services. News about Humana often centers on its Medicare Advantage and Medicaid activities, partnerships that expand care models, and initiatives that address social determinants of health and health equity.
Recent announcements highlight Humana’s focus on Medicare Advantage, including earnings guidance updates and investor communications disclosed through Form 8-K filings, as well as program-specific developments such as Humana USAA Honor Giveback plans that are designed with veterans’ needs in mind. These co-branded Medicare Advantage plans feature benefits like $0 copays for in-network primary care and in-network mental health services, Part B givebacks and coverage for dental, vision and hearing, while remaining available to any eligible Medicare beneficiary in the covered areas.
Humana news also reflects its emphasis on value-based care and integrated support for complex conditions. The company has announced a partnership with Atlas Oncology Partners to offer a coordinated oncology care model for eligible Humana Medicare Advantage members in Tennessee and Mississippi, bringing together interdisciplinary care teams, care coordination, psychosocial support and advanced supportive care. In parallel, CenterWell Senior Primary Care and Conviva Senior Primary Care have partnered with Thyme Care to provide continuous, oncology-focused support to eligible patients across several states.
Beyond insurance and clinical partnerships, Humana-related coverage includes updates from the Humana Foundation on research into loneliness among underserved boys and food insecurity among seniors, as well as community impact awards through Humana Healthy Horizons in Oklahoma to organizations addressing food, housing and employment needs. Visitors to this page can explore earnings-related updates, ratings actions from agencies such as AM Best, leadership transitions, philanthropic reports and community initiatives that illustrate how Humana combines insurance, care delivery and community investment.
Humana Inc. (NYSE: HUM) has elected David T. Feinberg, M.D., M.B.A., to its Board of Directors. With over 25 years of experience, Feinberg is currently the CEO of Cerner and previously led Google Health, enhancing healthcare initiatives using technology and innovation. Humana's Chairman, Kurt J. Hilzinger, emphasized Feinberg's expertise in improving clinical care and digital transformation as beneficial for the company's growth and strategy execution. This appointment increases Humana's board to 14 members.
Humana Inc. (NYSE: HUM) has announced that Chief Financial Officer Susan M. Diamond will present at the Barclays Global Healthcare Conference on Tuesday, March 15, 2022, at 9:30 a.m. Eastern time. Investors can access a live audio webcast of the presentation on Humana's Investor Relations page. The company emphasizes its commitment to integrated care, aiming to improve the health and well-being of its members while lowering costs. Humana supports healthcare professionals through various clinical capabilities and resources.
Humana Inc. (NYSE: HUM) announced a plan to enhance its Board of Directors by appointing two new independent directors as part of a cooperation agreement with Starboard Value LP. This initiative aims to improve corporate governance and align with the company's growth strategies. Humana reiterated its long-term earnings growth target of 11-15% and a $1 billion value creation goal by 2023, while also focusing on expanding its Medicare Advantage market share and increasing pre-tax margins.
Humana Inc. (NYSE: HUM) has declared a cash dividend of $0.7875 per share, reflecting a 12.5% increase from the previous $0.70 dividend. This dividend is payable on April 29, 2022, to stockholders of record as of March 31, 2022. Humana aims to enhance health outcomes and manage costs through integrated care, benefiting millions of members, including Medicare recipients and military personnel. The company provides a range of resources, such as in-home care and behavioral health services, to simplify healthcare access and improve member well-being.
Humana Inc. (NYSE: HUM), in collaboration with The Humana Foundation and the University of Louisville, announced a $25 million investment in the Health Equity Innovation Hub. This initiative aims to enhance health equity for marginalized populations in Louisville and beyond. The funding includes $1.5 million from Humana and up to $13.5 million from The Humana Foundation, marking one of the largest donations in UofL’s history. The Hub will focus on research, talent development, and entrepreneurship, addressing social determinants of health to improve overall health outcomes.
Humana Inc. (NYSE: HUM) has received notification from the Louisiana Department of Health to award a contract for providing Medicaid coverage in Louisiana. The Medicaid division, Humana Healthy Horizons, plans to commence service later this year, contingent on completing the protest period. The initiative aims to enhance health outcomes for 1.6 million Medicaid beneficiaries in Louisiana through a holistic care approach. This selection underscores Humana's commitment to improving community health and supporting urgent needs through programs addressing social determinants of health.
Humana Inc. (NYSE: HUM) announced that CEO Bruce D. Broussard will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 11:20 a.m. ET. Interested investors can access a live audio webcast on Humana’s Investor Relations page at humana.com. The company emphasizes its commitment to integrated healthcare, aiming to improve health and reduce costs for its members through various services, including in-home care and data analytics.
Summary not available.
Humana Specialty Pharmacy announced the addition of two oncology therapies: TAGRISSO® (osimertinib) for EGFRm non-small cell lung cancer and LENVIMA® (lenvatinib) for various cancers. These drugs will be delivered directly to patients, supported by Humana's Oncology Center of Excellence, which offers expert guidance on treatment. Humana is dedicated to enhancing patient experiences and health outcomes while managing chronic and complex illnesses through personalized services.
Humana reported a 4Q21 loss per common share of $0.11 on a GAAP basis, while adjusted EPS stood at $1.24. For FY 2021, GAAP EPS was $22.67, down from $25.31 in FY 2020. The company anticipates FY 2022 GAAP EPS of at least $23.08 and adjusted EPS of at least $24.00, considering a $1.00 negative COVID-19 impact. Humana plans to create $1 billion in value through cost savings and productivity initiatives, focusing on its Medicare Advantage business and healthcare services expansion.